Sunlenca® (Lenacapavir): A first-in-class, long-acting HIV-1 capsid inhibitor for treating highly multidrug-resistant HIV-1 infection

Sunlenca® (Lenacapavir): A first-in-class, long-acting HIV-1 capsid inhibitor for treating highly multidrug-resistant HIV-1 infection

Saved in:

Bibliographic Details
Main Authors:	Chunhua Ma, Junbiao Chang, Bin Yu
Format:	Article
Language:	English
Published:	Elsevier 2024-12-01
Series:	Acta Pharmaceutica Sinica B
Subjects:	Lenacapavir Capsid inhibitor HIV-1 infection HIV prevention Multidrug resistance Antiretroviral medication
Online Access:	http://www.sciencedirect.com/science/article/pii/S2211383524003290
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Impact of HIV-1 capsid polymorphisms on viral infectivity and susceptibility to lenacapavir
by: Derek Hansen, et al.
Published: (2025-05-01)

Genetic Diversity in the Capsid Protein-Coding Region of HIV-1 Circulating in Benguela, Angola: Implications for Primary Resistance to the Novel Capsid Inhibitor Lenacapavir
by: Gonçalo Queirós, et al.
Published: (2025-05-01)

Lenacapavir’s success: Revitalizing antiviral drug discovery
by: Daniel Miranda, et al.
Published: (2025-12-01)

Structural and mechanistic bases for resistance of the M66I capsid variant to lenacapavir
by: Lorenzo Briganti, et al.
Published: (2025-05-01)

Lenacapavir: a potential game changer for HIV prevention in the Americas, if the game is played equitably
by: Valeria D. Cantos, et al.
Published: (2025-07-01)

Spatiotemporal binding of cyclophilin A and CPSF6 to capsid regulates HIV-1 nuclear entry and integration
by: Zachary Ingram, et al.
Published: (2025-04-01)

How HIV-1 Uses the Metabolite Inositol Hexakisphosphate to Build Its Capsid
by: Leo C. James
Published: (2025-05-01)

Interplay between the cyclophilin homology domain of RANBP2 and MX2 regulates HIV-1 capsid dependencies on nucleoporins
by: Haley Flick, et al.
Published: (2025-03-01)

Investigation of Natural Resistance to Fostemsavir and Lenacapavir in Naïve Primary Infections by Ultra-Deep Sequencing of near Full-Length HIV-1 Genomes
by: Elisabetta Lazzari, et al.
Published: (2025-04-01)

Clinical Pharmacokinetics and Safety of a New HIV-1 Capsid Inhibitor, VH4004280, After Oral Administration in Adults Without HIV
by: Nilay Thakkar, et al.
Published: (2025-04-01)

Clinical Pharmacokinetics and Safety of Orally Administered VH4011499, a New HIV-1 Capsid Inhibitor, in Adults Without HIV
by: Nilay Thakkar, et al.
Published: (2025-04-01)

Interaction Mechanisms of Cold Atmospheric Plasmas with HIV Capsid Protein by Reactive Molecular Dynamics Simulation
by: Ying Sun, et al.
Published: (2024-12-01)

Modelling the immunopathogenesis of HIV-1 infection and the effect of multidrug therapy: The role of fusion inhibitors in HAART
by: Gesham Magombedze, et al.
Published: (2008-05-01)

The prevalence of resistance-associated mutations to protease and reverse transcriptase inhibitors in treatment-naïve (HIV1)-infected individuals in Casablanca, Morocco
by: Khadija Bakhouch, et al.
Published: (2009-06-01)

Expanding Treatment Opportunities: Reviewing the Current State of Injectable Antiretrovirals for Treatment of HIV
by: Amanda Binkley, et al.
Published: (2024-10-01)

Development of a risk stratification model for pharmaceutical care in HIV patients
by: Ramón Morillo-Verdugo, et al.
Published: (2017-05-01)

Bioinformatics study of selective inhibitor from <i>Garcinia mangostana</i> L. tackle HIV‑1 infection
by: V. D. Kharisma, et al.
Published: (2024-01-01)

Bone Mass Density in HIV/AIDS Patients
by: Nadia Ayu Mulansari, et al.
Published: (2016-12-01)

Dynamical Analysis of HIV/AIDS Epidemic Model with Treatment
by: Badria Ulfa, et al.
Published: (2018-02-01)

ANALYSIS AND OPTIMAL CONTROL OF HIV GROWTH MODEL IN THE BODY WITH ANTIRETROVIRAL THERAPY
by: Erlyana Trie Damayanti, et al.
Published: (2024-05-01)

PHARMACOECONOMIC MODELING OF ANTIRETROVIRAL DRUGS USE DURING TREATMENT OF HIV INFECTION
by: V. A. Chibilyaev, et al.
Published: (2015-03-01)

Allelic variants of human genes affecting HIV intracellular life cycle and regulating immune response to HIV infection
by: R. M. Khaitov, et al.
Published: (2019-05-01)

Characteristics of HIV-positive pregnant women and HIV- and antiretroviral therapy-exposed fetuses: A case-control study
by: Tung-Che Hung, et al.
Published: (2020-08-01)

HIV-1 and Antiretroviral Therapy Modulate HERV Pol and Syncytin Gene Expression in Mothers and Newborns
by: Anna Pau, et al.
Published: (2025-06-01)

Drug resistance mutations and phylogenetic analysis of HIV-1 subtypes B and F from mothers and children with vertical transmission
by: Aldicléya Lima Luz, et al.
Published: (2025-07-01)

The synergistic health syndemic of HIV and cancer of the cervix in women living with HIV in sub-Saharan Africa: Decrying the dearth of information
by: S Sibeko, et al.
Published: (2024-11-01)

A study of barriers to adherence of antiretroviral treatment in prisoners living with HIV in Tehran, Iran
by: Seyedahmad Seyedalinaghi, et al.
Published: (2020-06-01)

ASSESSMENT OF ECONOMIC EFFICIENCY OF APPLICATION OF RALTEGRAVIR BY PATIENTS WITHOUT EXPERIENCE OF TYPE 1 HIV INFECTION THERAPY IN RUSSIA
by: Elamin H. Elbasha, et al.
Published: (2015-09-01)

Efficacy and safety of treatment of HIV-associated multidrug-resistant tuberculosis. Systematic review and meta-analysis
by: A. V. Kukurika
Published: (2025-03-01)

Isolating the effects of HIV infection and HIV exposure on epigenetic profiles in infants using historical data from the Mothers and Infants Cohort StudyResearch in context
by: Jasmine Douglas, et al.
Published: (2025-05-01)

Predictors of virological outcomes in patients with HIV on antiretroviral therapy in Osogbo, Nigeria: a cross-sectional study
by: Funso Abidemi Olagunju, et al.
Published: (2025-05-01)

Analysis of survival of HIV-infected patients depending on various factors
by: D. M. Urunova, et al.
Published: (2024-12-01)

Potential interactions in a cohort of elderly hiv-positive patients
by: María Núñez-Núñez, et al.
Published: (2018-07-01)

Prevalence and determinants of nonadherence to highly active antiretroviral therapy among people living with HIV/AIDS in Ibadan, Nigeria
by: Samuel A. Olowookere, et al.
Published: (2008-10-01)

Feasibility and staff acceptability of implementing Xpert HIV-1 viral load point-of-care testing: a pilot study in San Francisco
by: Kelvin Moore Jr., et al.
Published: (2025-01-01)

Genetic subtypes and drug resistance in untreated patients with HIV-1 infection in Qingdao, China: An analysis of 113 cases
by: WANG Hong, LI Hongbo, SUN Chunfeng, LI Xiang, XU Guangyong
Published: (2025-02-01)

HIV Infection and Antiretroviral Therapy Impair Liver Function in People Living with HIV: Systematic Review and Meta-Analysis
by: Kay-Lee E. Strauss, et al.
Published: (2025-06-01)

HIV-associated neurocognitive disorders in Africa: challenges, peculiarities, and future directions
by: Tobi Olajide, et al.
Published: (2024-11-01)

Multimodal radiomics integrating deep learning and clinical features for diagnosing multidrug-resistant tuberculosis in HIV/AIDS patients
by: Chang Song, et al.
Published: (2025-06-01)

Panhypopituitarism in HIV patient receiving antiretroviral therapy
by: Tatyana B. Morgunova, et al.
Published: (2021-12-01)